Article

Anuja Bandyopadhyay, MD: Understanding the Risk of Obstructive Sleep Apnea in Infants

Author(s):

Infants with obstructive sleep apnea may also be at an increased risk of negative outcomes associated with COVID-19.

There remains a knowledge gap as to why some infants develop obstructive sleep apnea (OSA) and present different symptoms than older children.

In a retrospective chart review planned for presentation at the American Thoracic Society (ATS) 2020 International Conference, investigators from the Riley Children’s Hospital at Indiana University Health, are trying to understand this patient population better in an effort to improve care and treatment.

One of the potential reasons the knowledge of infants with the disease is low is because it was previously thought that sleep apnea in older children is similar to having sleep apnea in infants.

However, in infants it is now known that the upper airway is more collapsible and softer in infants. It isn’t until an infant is 1 or 2 years old that their airways strengthen.

Knowing this about the anatomy of infants can further the understanding of how they can be impacted by sleep apnea.

In an interview with HCPLive®, Anuja Bandyopadhyay, MD, Pediatric Pulmonology, Allergy and Sleep Medicine, Riley Children’s Hospital, acknowledged what those knowledge gaps are in terms of treatment and understanding of the disease and how researchers can begin to close this gap.

Another area of concern is the coronavirus disease 2019 (COVID-19). Bandyopadhyay explained how infants with obstructive sleep apnea could be at a higher risk of some of the more negative outcomes associated with the virus than infants who do not have OSA.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.